Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00537719 | Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo. | PHASE1 | COMPLETED | 34 | — | — | Dec 7, 2007 | Apr 4, 2008 | Aug 17, 2017 | 1 | United States |
| NCT00530309 | Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus | PHASE1 | COMPLETED | 40 | — | — | Aug 1, 2007 | Apr 17, 2008 | Aug 17, 2017 | 3 | Japan |
| Arm | Type | Description |
|---|---|---|
| GSK716155 | ACTIVE_COMPARATOR | albiglutide subcutaneous injection |
| placebo | PLACEBO_COMPARATOR | placebo injection |
| Subjects receiving GSK716155 + placebo | EXPERIMENTAL | Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo. |
| Name | Type | Description |
|---|---|---|
| GSK716155 | DRUG | albiglutide subcutaneous injection |
| Placebo | DRUG | placebo injection |
| GSK716155 for injection | DRUG | GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. |
Inclusion Criteria: * Healthy men or women, between the ages of 18 and 65, and have a Body Mass Index (BMI) of between 20 and 32. * If female, the subject must be not be capable of having children. Exclusion Criteria: * Subjects must not use tobacco, nicotine, or illegal drugs of abuse, and must ...